Spravato: First Monotherapy FDA Approved for Treatment-Resistant MDD
Treatment-resistant depression (TRD) remains a significant challenge for clinicians and patients alike, often requiring innovative strategies beyond traditional antidepressants. A groundbreaking step in addressing this…